14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:CNAT
Delisted

Conatus Pharmaceuticals Inc. Stock Price (Quote)

$0.255
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $0.255 $0.255 Friday, 27th May 2022 CNAT stock ended at $0.255. During the day the stock fluctuated 0% from a day low at $0.255 to a day high of $0.255.
90 days $0.238 $0.275
52 weeks $0.203 $1.23

Historical Conatus Pharmaceuticals Inc. prices

Date Open High Low Close Volume
Feb 09, 2022 $0.235 $0.250 $0.235 $0.246 871 054
Feb 08, 2022 $0.240 $0.249 $0.227 $0.239 637 885
Feb 07, 2022 $0.230 $0.249 $0.221 $0.239 821 517
Feb 04, 2022 $0.230 $0.231 $0.203 $0.231 1 289 394
Feb 03, 2022 $0.234 $0.234 $0.218 $0.229 612 858
Feb 02, 2022 $0.243 $0.247 $0.223 $0.234 1 218 236
Feb 01, 2022 $0.242 $0.249 $0.229 $0.246 718 436
Jan 31, 2022 $0.220 $0.238 $0.211 $0.238 844 754
Jan 28, 2022 $0.212 $0.230 $0.203 $0.218 559 817
Jan 27, 2022 $0.244 $0.244 $0.205 $0.219 1 724 752
Jan 26, 2022 $0.232 $0.255 $0.222 $0.224 1 358 648
Jan 25, 2022 $0.240 $0.258 $0.231 $0.237 908 619
Jan 24, 2022 $0.250 $0.250 $0.220 $0.240 1 261 144
Jan 21, 2022 $0.280 $0.280 $0.252 $0.258 750 111
Jan 20, 2022 $0.290 $0.290 $0.260 $0.269 303 662
Jan 19, 2022 $0.275 $0.295 $0.261 $0.281 1 032 827
Jan 18, 2022 $0.271 $0.276 $0.261 $0.275 868 029
Jan 14, 2022 $0.270 $0.279 $0.261 $0.265 984 991
Jan 13, 2022 $0.280 $0.280 $0.265 $0.265 728 591
Jan 12, 2022 $0.283 $0.291 $0.271 $0.277 958 336
Jan 11, 2022 $0.282 $0.291 $0.278 $0.285 571 778
Jan 10, 2022 $0.309 $0.313 $0.277 $0.284 1 786 692
Jan 07, 2022 $0.316 $0.325 $0.301 $0.310 987 968
Jan 06, 2022 $0.317 $0.326 $0.301 $0.312 818 196
Jan 05, 2022 $0.353 $0.355 $0.314 $0.321 384 956
Click to get the best stock tips daily for free!

About Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals. Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sust... CNAT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT